HBIO · Insider Trading
Harvard Bioscience Inc
Every open-market purchase and sale reported by HBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Katherine A. Eade | Director | A | +16,556 | — |
| 2026-06-11 | Robert E. Gagnon | Director | A | +16,556 | — |
| 2026-06-11 | Stephen J Denelsky | Director | A | +16,556 | — |
| 2026-06-11 | Seth Benjamin Benson | Director | A | +16,556 | — |
| 2026-06-11 | William Snider | Director | A | +16,556 | — |
| 2026-04-01 | Mark T Frost | Chief Financial Officer | Buy | +5,000 | +$25.00K |
| 2026-04-01 | Mark T Frost | Chief Financial Officer | A | +30,000 | — |
| 2026-03-23 | John D Duke | Chief Executive Officer | A | +75,000 | — |
| 2026-03-18 | William Snider | Director | Buy | +21,000 | +$103.60K |
| 2026-03-18 | Stephen J Denelsky | Director | Buy | +10,000 | +$48.70K |
| 2026-03-17 | John D Duke | Chief Executive Officer | Buy | +5,000 | +$25.05K |
| 2025-12-30 | William Snider | Director | A | +110,000 | — |
| 2025-10-07 | Stephen J Denelsky | Director | A | +110,000 | — |
| 2025-08-19 | James W Green | Director | MIXED | −392,522 | −$23.67K |
| 2025-08-11 | John D Duke | Chief Executive Officer | A | +1,000,000 | — |
| 2025-07-25 | Seth Benjamin Benson | Director | A | +110,000 | — |
| 2025-07-18 | Robert E. Gagnon | Director | A | +110,000 | — |
| 2025-07-18 | Katherine A. Eade | Director | A | +110,000 | — |
| 2025-05-14 | Mark T Frost | Interim CFO | A | +100,000 | — |
| 2025-03-21 | Jennifer Cote | Chief Financial Officer | F | −5,687 | −$3.92K |
| 2025-03-21 | James W Green | Chief Executive Officer | F | −38,413 | −$26.45K |
| 2025-01-03 | James W Green | Chief Executive Officer | D | −145,365 | — |
| 2024-12-31 | James W Green | Chief Executive Officer | F | −82,225 | −$162.81K |
| 2024-12-31 | Jennifer Cote | Chief Financial Officer | F | −8,528 | −$16.89K |
| 2024-06-14 | James W Green | Chief Executive Officer | Buy | +10,000 | +$29.10K |
| 2024-06-07 | James W Green | Chief Executive Officer | Buy | +20,000 | +$61.40K |
| 2024-05-23 | Thomas W Loewald | Director | A | +45,872 | — |
| 2024-05-23 | Alan I Edrick | Director | A | +45,872 | — |
| 2024-05-23 | Katherine A. Eade | Director | A | +45,872 | — |
| 2024-05-23 | Bertrand Loy | Director | A | +56,575 | — |
| 2024-03-07 | James W Green | Chief Executive Officer | A | +429,594 | — |
| 2024-03-07 | Jennifer Cote | Chief Financial Officer | MIXED | +61,680 | −$40.77K |
| 2024-01-03 | Jennifer Cote | Chief Financial Officer | F | −5,910 | −$31.62K |
| 2024-01-03 | James W Green | Chief Executive Officer | F | −211,182 | −$1.13M |
| 2023-08-21 | James W Green | Chief Executive Officer | Buy | +25,000 | +$109.50K |
| 2023-06-13 | James W Green | Chief Executive Officer | F | −48,373 | −$264.12K |
| 2023-05-23 | Thomas W Loewald | Director | A | +25,554 | — |
| 2023-05-23 | Alan I Edrick | Director | A | +25,554 | — |
| 2023-05-23 | Bertrand Loy | Director | A | +31,516 | — |
| 2023-05-23 | Katherine A. Eade | Director | A | +25,554 | — |
| 2023-03-16 | Alan I Edrick | Director | Buy | +30,000 | +$79.29K |
| 2023-03-15 | James W Green | Chief Executive Officer | Buy | +40,000 | +$105.40K |
| 2023-03-08 | Jennifer Cote | Interim CFO | A | +82,634 | — |
| 2023-03-08 | James W Green | Chief Executive Officer | A | +692,750 | — |
| 2023-01-03 | James W Green | Chief Executive Officer | F | −125,509 | −$330.90K |
| 2023-01-03 | Michael A. Rossi | Chief Financial Officer | F | −9,960 | −$25.40K |
| 2022-12-02 | James W Green | Chief Executive Officer | Buy | +30,000 | +$75.30K |
| 2022-09-15 | Bertrand Loy | Director | J | −108,715 | — |
| 2022-08-29 | Bertrand Loy | Director | Buy | +9,291 | +$31.68K |
| 2022-08-26 | Bertrand Loy | Director | Buy | +25,535 | +$83.38K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James W Green | Chief Executive Officer | 406,278 | $3.38M |
| John D Duke | Chief Executive Officer | 180,000 | $1.50M |
| Katherine A. Eade | Director | 58,669 | $488.13K |
| William Snider | Director | 48,556 | $403.99K |
| Mark T Frost | Chief Financial Officer | 47,500 | $395.20K |
| Stephen J Denelsky | Director | 37,556 | $312.47K |
| Robert E. Gagnon | Chief Financial Officer | 27,556 | $229.27K |
| Seth Benjamin Benson | Director | 27,556 | $229.27K |
| Jennifer Cote | Chief Financial Officer | 15,902 | $132.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HBIO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.